Long-term demographic trends are all pointing to the same things: larger and older populations. Currently in Japan, more than 25% of the total population is age 65 and older. Analysts expect nearly 40% of the nation's population to be in this group by 2050. In the United States, more than 70 million individuals will become Medicare beneficiaries over the next two decades. Similar stories abound across developed Europe and Asia. In the emerging world, exploding populations will require new healthcare solutions as well. Continued development across the healthcare sector is critical, and innovation remains the life blood of the biotech and pharmaceutical industry. It is in this innovation and advancement that investors can find long-term profit.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Higher R&D Equal Bigger Sales
According to a study released in March by PhRMA and Burrill, overall biotech and pharma spending on R&D in 2010 increased by $1.5 billion, to a record-high $67.4 billion. Given the current sluggish economy, some analysts think that R&D spending will fall over the next few years. However, the long-term trend points towards higher research and development budgets. So far, the major pharmaceutical firms have not been successful in replenishing its pipelines and tired growing via biotech acquisitions. While this has worked in some instances, the truth is that internally derived drugs have a 20% higher chance of making it to market and smaller biotechs (big pharma's buyout targets) still need to spend major dollar amounts on R&D. (These analytical methods will help you size up a biotech company and make a winning investment. For more, see How To Do Qualitative Analysis On Biotech Companies.)

The life science equipment industry could be a great bet on the need for new healthcare solutions and offer some of the most attractive risk/reward opportunities in the sector. These "picks and shovels" providers of both high tech molecular diagnostic and sequencing equipment, along with basic lab needs, are the major recipients of all of this R&D spending. Sales of next-generation sequencing products have grown from just $50 million in 2006 to well over $520 million by 2009. Overall, life science companies saw a 14% increase in combined instrument sales in 2010, reaching nearly $25 billion.

In addition, the recent market downturn has many investors looking to reduce their risk profiles. The steady growth of life science equipment firms makes them an attractive alternative to higher-risk investments like RXi Pharmaceuticals (Nasdaq:RXII).

A Next-Gen Portfolio
For investors, the life sciences tools industry offers one of the better ways to play healthcare. While there is no dedicated ETF for the sector, the iShares Nasdaq Biotechnology (NYSE:IBB) does have some limited exposure to a few equipment firms like Qiagen (Nasdaq:QGEN). However, the best way to play the sector is through individual names. Here are a few picks. (For related reading on ETFs, see 5 ETF Flaws You Shouldn't Overlook.)

Starting off as company that made grocery scales in the early 1900s, Mettler-Toledo (NYSE:MTD) has transformed itself into the premier firm in precision instruments. Offering balances, pipettes and analytical equipment. The company recently reported a robust 23% in earnings during the second quarter versus the year ago period, and has seen an increase in insider buying activity. Also seeing heavy insider buying recently has been chromatography firm Waters (NYSE:WAT).

For investors wanting to focus on the largest firms in the sector, the trio of Agilent Technologies (NYSE:A), Life Technologies (Nasdaq:LIFE) and Thermo Fisher Scientific (NYSE:TMO) were the top three earners for 2010. Growing through internal R&D and acquisition, these three firms should continue to be on top for the remainder of 2011 into the future.

Finally as a side play on the growth of the life science's industry, REIT Alexandria (NYSE:ARE) owns and operates 159 different lab buildings across the United States and Canada. The stock currently yields 2.7% and could be a good way to add some income potential from the life sciences industry.

The Bottom Line
Finding new healthcare solutions will be a paramount concern going forward. To that end, R&D spending by major pharmaceutical and biotech firms will see increases. For investors, the best way to profit from this increased spending is through the life science equipment makers. Firms like Affymetrix (Nasdaq:AFFX) make ideal portfolio solutions to play the end for innovation. (For related reading, see Using DCF In Biotech Valuation.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Chart Advisor

    Bumpy Roads Ahead In Transportation

    Investors are keeping an eye on the transportation industry. We'll take a look at the trend direction and how to trade it.
  2. Investing

    How ETFs May Save You Thousands

    Being vigilant about the amount you pay and what you get for is important, but adding ETFs into the investment mix fits well with a value-seeking nature.
  3. Mutual Funds & ETFs

    3 Fixed Income ETFs in the Mining Sector

    Learn about the top three metals and mining exchange-traded funds (ETFs), and explore analyses of their characteristics and how investors can benefit from these ETFs.
  4. Chart Advisor

    Agriculture Commodities Are In The Bear's Sights

    Agriculture stocks have experienced strong moves higher over recent weeks, but chart patterns on sugar, corn and wheat are suggesting the moves could be short lived.
  5. Investing News

    Top Tips for Diversifying with Mutual Funds

    Are mutual funds becoming obsolete? If they have something to offer, which funds should you consider for diversification?
  6. Professionals

    Top Stocks to Short, Go Long On to Beat the Market

    A long/short portfolio can help weather a variety of market scenarios. Here's how to put one together.
  7. Mutual Funds & ETFs

    Top 4 Asia-Pacific ETFs

    Learn about four of the best-performing exchange-traded funds, or ETFs, that offer investors exposure to the Asia-Pacific region.
  8. Mutual Funds & ETFs

    Top 3 Japanese Bond ETFs

    Learn about the top three exchange-traded funds (ETFs) that invest in sovereign and corporate bonds issued by developed countries, including Japan.
  9. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  10. Savings

    Become Your Own Financial Advisor

    If you have some financial know-how, you don’t have to hire someone to advise you on investments. This tutorial will help you set goals – and get started.
  1. Can mutual funds invest in IPOs?

    Mutual funds can invest in initial public offerings (IPOS). However, most mutual funds have bylaws that prevent them from ... Read Full Answer >>
  2. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. Does index trading increase market vulnerability?

    The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>
  6. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!